Article

Phakic toric IOL corrects total refractive error

Mainz, Germany-A phakic toric IOL is beneficial in correcting myopia and hyperopia as well as regular astigmatism in the range of 2 to 7 D, according to H. Burkhard Dick, MD, one of the investigators who reported on the multicenter clinical trial of the lens.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Related Content
Palatin releases updated results from responder analyses of phase 3 Melody-1 trial in dry eye
April 29th 2025

Palatin releases updated results from responder analyses of phase 3 Melody-1 trial in dry eye

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR
April 28th 2025

Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Red light therapy in children with myopia
April 27th 2025

Red light therapy in children with myopia

Allotex appoints Michael Mrochen as CEO
April 26th 2025

Allotex appoints Michael Mrochen as CEO

© 2025 MJH Life Sciences

All rights reserved.